News

DurAVR™ is made using ADAPT® tissue, Anteris’ patented anti-calcification tissue technology.

The detailed results from SELECT will be presented at a scientific conference later in 2023.

Utilizing deep learning technology in real-time, Alphenix / Evolve Edition is designed to enhance imaging while enabling reduced time and radiation dose during routine and complex percutaneous coronary intervention (PCI) and structural heart...

BOSTON, MA — The Society of Cardiovascular Computed Tomography (SCCT) presented three winners of the Best Abstract Awards — supported by the Cardiovascular Research Foundation of Southern California (CVRF of So. Ca.) - Ma Family — at their...

"There is a great need to generate high-quality evidence to guide clinical decision-making for such procedures in women and minority groups who have been underrepresented in most prior studies,” explained Gregg W. Stone, MD.

 After decades of decline, fatal coronary heart disease may rise again unless Americans modify three major risk factors: smoking, drinking, and obesity.

The study evaluated using the StatSeal® Advanced Plus Disc (Biolife, LLC) for femoral vein groin closure of AF ablation patients who remained on their anticoagulation medications.

The pathway will augment Geisinger’s existing remote heart failure (HF) management program by incorporating the FDA-cleared Bodyport Cardiac Scale and Fluid Alerts.

(New York, NY) - The cardiovascular polypill, developed by the Spanish National Centre for Cardiovascular Research (CNIC) and the pharmaceutical company Ferrer, has been included by the World Health Organization (WHO) in its List of Essential...

Three new codes, MS-DRGs 323, 324, and 325, have been created to describe Percutaneous Coronary Interventions (PCI) that utilize coronary IVL, with and without a stent implant (intraluminal device), in the hospital inpatient setting.